 After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseidos full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss. VANCOUVER, BC ACCESSWIRE October 18, 2021 RepliCel Life Sciences Inc. OTC PINK:REPCFTSXV:RPFRA:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, announced today it has retained Aceris Law LLC, a law firm specialized in international arbitration, to pursue the resolution of its disagreement with Shiseido Company Limited Shiseido. 